Skip to main content
    C

    Coeptis Therapeutics Inc (COEP)

    Official site

    BIOTECHNOLOGY

    $16.40
    +0.19 (+1.17%)

    Last updated: Apr 24, 2026 at 5:00 PM ET

    Coeptis Therapeutics Inc (COEP) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in US dollars.

    Coeptis Therapeutics reported revenue of $1.36M for the fiscal year ended Dec 31, 2025. That year, net income was -$12.28M with a net margin of -900.7%, operating cash flow was -$8.60M and free cash flow was -$8.60M. The quarter ended Jun 30, 2026 had revenue of $3.17M and net income of -$27.52M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.36MN/A86.7%-956.9%-900.7%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$75.00KN/A100.0%-18727.9%-17932.4%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Dec 2005N/AN/AN/AN/AN/A
    Dec 2004N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2004 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2005Dec 2004
    Revenue$1.36M$0$0$0$75.00K$0$0N/AN/AN/A
    Cost of revenue$180.63K$0$0$0$0$0$0N/AN/AN/A
    Gross profit$1.18M$0$0$0$75.00K$0$0N/AN/AN/A
    Research and development$1.28M$2.33M$6.67M$20.89K$0$0$0$0$0$0
    Operating income-$13.04M-$10.05M-$21.49M-$34.20M-$14.05M-$68.43K-$2.23KN/A-$308.00K-$10.08K
    Net income-$12.28M-$10.88M-$21.27M-$37.57M-$13.45M-$17.28M-$2.23K-$7.07K-$344.00K$2.65M
    EBITDA-$9.82M-$9.40M-$20.12M-$32.96M-$13.81MN/A-$2.23K-$7.07KN/A$2.65M
    Fiscal years ended Dec 2004 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$3.17M$113.77K$862.05K$237.44K$0$62.87K$1.86M$0$0$0$1.50M$0
    Gross profit-$1.77M$68.61K$816.89K$192.29K$0$17.72K-$259.98K$0$0$0-$250.31K$0
    Operating income-$13.79M-$3.91M-$1.99M-$2.48M$0-$4.06M-$2.16M-$2.14M-$2.83M-$2.92M-$3.37M-$7.90M
    Net income-$27.52M-$7.94M-$1.62M-$2.90M$0-$6.78M-$3.01M-$1.83M-$3.04M-$3.00M-$3.76M-$6.35M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $250.00K exceeded cash and equivalents by $248.60K.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2005Dec 2004
    Total assets$1.40K$8.91M$4.57M$7.92M$6.77M$76.71M$171.54K$80.00K$153.56K$46.92K
    Current assets$1.40K$1.05M$1.75M$3.94M$2.18M$959.00K$505$1.22M$153.56K$383
    Cash and equivalents$1.40K$532.88K$1.47M$3.79M$2.18M$907.18K$505N/A$153.56K$383
    Total liabilities$120$5.04M$3.76M$3.46M$4.41M$22.95M$155.85K$62.07K$705.22K$310.94K
    Short-term debt$100.00K$1.19M$975.00K$1.85M$2.42M$1.92M$152.64K$62.07K$650.00K$95.00K
    Long-term debt$150.00K$150.00K$150.00K$150.00K$1.65M$150.00KN/AN/AN/AN/A
    Shareholder equity$1.28K$3.38M$813.96K$4.45M$2.35M-$22.00M$15.69K$17.93K-$551.66K-$264.01K
    Fiscal years ended Dec 2004 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$134.51M$19.79M$19.84M$14.18M$12.19M$13.45M$8.91M$8.96M$4.20M$3.89M$7.16M$4.67M
    Total liabilities$2.03M$2.21M$2.09M$3.26M$5.11M$5.99M$5.04M$3.97M$4.51M$5.03M$4.67M$2.78M
    Cash and equivalents$15.49M$5.21M$5.67M$4.91M$2.00M$4.27M$532.88K$1.14M$1.56M$1.03M$3.24M$1.41M
    Shareholder equity$132.48M$17.18M$17.25M$10.37M$6.10M$6.48M$3.19M$4.82M-$442.55K-$1.14M$2.49M$1.89M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$8.60M-$6.65M-$7.24M-$3.88M-$4.49M-$115.69K-$1.78K-$839.06K
    Capital expenditures$0$4$0$0$1.75M$0$35$2.79K
    Free cash flow-$8.60M-$6.65M-$7.24M-$3.88M-$6.24M-$115.69K-$1.82K-$841.85K
    Dividends paidN/AN/AN/AN/A$77.59KN/AN/AN/A
    Share repurchasesN/AN/AN/AN/A$247.16K$324.98K$88.28KN/A
    Investing cash flow$0$0$0$0-$1.75M-$75.75M$0$632.87K
    Financing cash flow$13.74M$5.71M$4.92M$5.49M$8.22M$76.77M$2.29K$594.08K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow$1.56M-$1.76M-$1.69M-$2.15M$2.37M-$2.37M-$1.44M-$1.89M-$1.42M-$1.90M-$1.69M-$1.96M
    Capital expendituresN/AN/A$0$3$0$0$1$0$1$0$0$0
    Free cash flowN/AN/A-$1.69M-$2.15M$2.37M-$2.37M-$1.44M-$1.89M-$1.42M-$1.90M-$1.69M-$1.96M
    Last 12 quarters

    Frequently Asked Questions About COEP

    What is Coeptis Therapeutics' annual revenue?

    Coeptis Therapeutics reported revenue of $1.36M for the fiscal year ended Dec 31, 2025.

    Is Coeptis Therapeutics profitable?

    No. Coeptis Therapeutics reported net income of -$12.28M for the fiscal year ended Dec 31, 2025, with a net margin of -900.7%.

    How much free cash flow does COEP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$8.60M minus capital expenditures of $0 produced free cash flow of -$8.60M.

    How much debt does Coeptis Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $150.00K, short-term debt of $100.00K and cash and equivalents of $1.40K.

    What is COEP's profit margin?

    For the fiscal year ended Dec 31, 2025, Coeptis Therapeutics reported gross margin of 86.7%, operating margin of -956.9% and net margin of -900.7%.